Sarep­ta march­es for­ward with its po­ten­tial DMD gene ther­a­py and an ex­pand­ed Catal­ent man­u­fac­tur­ing deal

Sarep­ta spent much of last year march­ing for­ward with its can­di­date SRP-9001, a gene ther­a­py treat­ment for the rare but fa­tal Duchenne mus­cu­lar dy­s­tro­phy, even­tu­al­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER